Michael S. Ip
YOU?
Author Swipe
View article: Intravitreal Aflibercept for the Treatment of Diabetic Retinopathy Among Patients Who Completed PANORAMA: 1-Year Outcomes from the VOYAGE Extension Study
Intravitreal Aflibercept for the Treatment of Diabetic Retinopathy Among Patients Who Completed PANORAMA: 1-Year Outcomes from the VOYAGE Extension Study Open
Background/Objectives: Evaluate outcomes and treatment patterns with 2 mg intravitreal aflibercept injection among patients who completed the phase 3 PANORAMA trial and enrolled in the VOYAGE (ClinicalTrials.gov identifier, NCT04708145; 12…
View article: Comparative Analysis of Ocular Adverse Events between Aflibercept 8 mg and Faricimab
Comparative Analysis of Ocular Adverse Events between Aflibercept 8 mg and Faricimab Open
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
View article: Brolucizumab for Diabetic Macular Edema in Participants with/without prior Anti-VEGF Exposure
Brolucizumab for Diabetic Macular Edema in Participants with/without prior Anti-VEGF Exposure Open
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
View article: Pilot evaluation of Mepitel Film and StrataXRT for the prophylaxis of radiation dermatitis in Chinese breast cancer patients undergoing adjuvant radiotherapy in Hong Kong
Pilot evaluation of Mepitel Film and StrataXRT for the prophylaxis of radiation dermatitis in Chinese breast cancer patients undergoing adjuvant radiotherapy in Hong Kong Open
MF and StrataXRT were well tolerated and safe in Chinese BC patients. Larger randomized studies are needed to understand which patients could benefit more from these products.
View article: Treatment Patterns and Long-term Outcomes with Anti–VEGF Therapy for Retinal Vein Occlusion
Treatment Patterns and Long-term Outcomes with Anti–VEGF Therapy for Retinal Vein Occlusion Open
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
View article: Designing the next generation of clinical trials in intermediate AMD-a consensus driven, pragmatic, proof of concept early intervention study
Designing the next generation of clinical trials in intermediate AMD-a consensus driven, pragmatic, proof of concept early intervention study Open
A greater understanding of the pathophysiology of AMD has yielded potential therapeutic strategies for slowing vision loss. Structural imaging biomarkers and novel functional outcomes, both under intensive study as surrogate endpoints in A…
View article: Photoreceptor Function and Structure in Retinal Areas With Intraretinal Hyperreflective Foci in Age-Related Macular Degeneration
Photoreceptor Function and Structure in Retinal Areas With Intraretinal Hyperreflective Foci in Age-Related Macular Degeneration Open
IHRF presence is associated with localized reduced visual function and photoreceptor degeneration in intermediate AMD. Prospective studies are warranted to further investigate the mechanisms of photoreceptor and sensitivity loss in the con…
View article: Long-Term Effects of Intravitreal Ranibizumab Compared With Panretinal Photocoagulation on Optical Coherence Tomography Measured Choroidal Thickness and Vascularity
Long-Term Effects of Intravitreal Ranibizumab Compared With Panretinal Photocoagulation on Optical Coherence Tomography Measured Choroidal Thickness and Vascularity Open
Ranibizumab treatment for PDR did not statistically significantly affect choroidal thickness or vascularity differently than PRP.
View article: The Progression of Stargardt Disease (ProgStar) as determined by spectral-domain optical coherence tomography over a 24-month period (ProgStar Report No. 19)
The Progression of Stargardt Disease (ProgStar) as determined by spectral-domain optical coherence tomography over a 24-month period (ProgStar Report No. 19) Open
Introduction: To evaluate the progression of atrophy as determined by spectral-domain optical coherence tomography (SD-OCT) in patients with molecularly confirmed ABCA4-associated Stargardt disease type 1 (STGD1) over a 24-month period in …
View article: SUPPLEMENTAL DEXTROSE IN THE INFUSION FLUID DURING DIABETIC VITRECTOMY
SUPPLEMENTAL DEXTROSE IN THE INFUSION FLUID DURING DIABETIC VITRECTOMY Open
Purpose: Historically, supplemental dextrose to infusion fluid has been used to reduce the need for intraoperative lensectomies to maintain visualization during diabetic vitrectomy. Valved, small-gauge vitrectomy has reduced surgical time …
View article: Prediction of Long-Term Treatment Outcomes for Diabetic Macular Edema Using a Generative Adversarial Network
Prediction of Long-Term Treatment Outcomes for Diabetic Macular Edema Using a Generative Adversarial Network Open
The implementation of this tool may help identify potential nonresponders after long-term treatment, thereby facilitating management planning for these eyes.
View article: Real-World Safety Outcomes with Brolucizumab in Neovascular Age-Related Macular Degeneration: Findings from the IRIS® Registry
Real-World Safety Outcomes with Brolucizumab in Neovascular Age-Related Macular Degeneration: Findings from the IRIS® Registry Open
In this large real-world brolucizumab safety study, 3.4% of eyes experienced an IOI, RV, and/or RO event. Among eyes that experienced an adverse event for which VA data were available, median ETDRS vision change was 0 letters (IQR - 7 to +…
View article: Considerations for the Identification and Management of Geographic Atrophy: Recommendations from an Expert Panel
Considerations for the Identification and Management of Geographic Atrophy: Recommendations from an Expert Panel Open
Newly approved treatments for patients with geographic atrophy are changing the treatment paradigm, highlighting the need for eye care providers (ECPs) to have a set of recommendations on how to best manage GA patients. Here, we outline ho…
View article: Efficacy and Safety of Brolucizumab for Diabetic Macular Edema
Efficacy and Safety of Brolucizumab for Diabetic Macular Edema Open
Importance Despite the effectiveness of existing anti–vascular endothelial growth factor (VEGF) therapies, a need remains for further treatment options to improve response rates and/or reduce injection or monitoring frequency in patients w…
View article: Intraocular Pressure in Eyes With Retinal Vein Occlusion Compared With Fellow Eyes
Intraocular Pressure in Eyes With Retinal Vein Occlusion Compared With Fellow Eyes Open
This cohort study investigates intraocular pressure (IOP) in eyes with retinal vein occlusion (RVO) compared with fellow, unaffected eyes.
View article: Geographic Atrophy Management Consensus (GA-MAC): a Delphi panel study on identification, diagnosis and treatment
Geographic Atrophy Management Consensus (GA-MAC): a Delphi panel study on identification, diagnosis and treatment Open
Background/aims With a paradigm shift in geographic atrophy (GA) treatments now available, establishing consensus on the identification and diagnosis of the disease along with considerations for management of patients with GA will assist e…
View article: High Variation in Inner Retinal Reflectivity Predicts Poor Visual Outcome in Patients With Central Retinal Vein Occlusion: SCORE2 Report 21
High Variation in Inner Retinal Reflectivity Predicts Poor Visual Outcome in Patients With Central Retinal Vein Occlusion: SCORE2 Report 21 Open
Pixel heterogeneity in three-dimensional OCT data may serve as measure of disruption of the retinal laminations, and this factor may carry visually prognostic value.
View article: Macular Sensitivity Endpoints in Geographic Atrophy
Macular Sensitivity Endpoints in Geographic Atrophy Open
Proprietary or commercial disclosure may be found after the references.
View article: Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial
Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial Open
Importance Retinal vein occlusion is the second most common retinal vascular disease. Bevacizumab was demonstrated in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) to be noninferior to aflibercept with respect t…
View article: Visit Adherence and Visual Acuity in Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2)
Visit Adherence and Visual Acuity in Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) Open
Visit adherence is associated with VALS outcomes in CRVO patients.
View article: IMPACT OF RETINAL FLUID-FREE MONTHS ON OUTCOMES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
IMPACT OF RETINAL FLUID-FREE MONTHS ON OUTCOMES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Open
Purpose: To assess the effect of the total number of fluid-free months after loading on visual and anatomical outcomes in neovascular age-related macular degeneration patients receiving anti–vascular endothelial growth factor therapy. Meth…
View article: Mechanisms of Epithelial-Mesenchymal Transition and Prevention of Dispase-Induced PVR by Delivery of an Antioxidant αB Crystallin Peptide
Mechanisms of Epithelial-Mesenchymal Transition and Prevention of Dispase-Induced PVR by Delivery of an Antioxidant αB Crystallin Peptide Open
Proliferative Vitreoretinopathy (PVR) is a refractory retinal disease whose primary pathogenesis involves the epithelial-mesenchymal transition (EMT) of retinal pigment epithelial (RPE) cells. At present, there is no effective treatment ot…